MPS-102

MPS-102 is an orally bioavailable, small molecule multi-kinase inhibitor developed by the Fondazione Ricerca Traslazionale (FoRT). It is designed to target several key pathways involved in tumor growth, survival, and angiogenesis, specifically inhibiting the Hepatocyte Growth Factor Receptor (MET), Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), AXL receptor tyrosine kinase, and Tyrosine-protein kinase receptor Tie-2. By targeting MET, MPS-102 aims to address resistance mechanisms in non-small cell lung cancer (NSCLC), particularly in patients where MET signaling provides a bypass for EGFR inhibition. The additional inhibition of VEGFR2 and Tie-2 provides anti-angiogenic properties, while AXL inhibition addresses epithelial-to-mesenchymal transition (EMT) and further drug resistance. MPS-102 has been investigated in early-phase clinical trials for patients with advanced solid tumors and NSCLC.